

Application No. 10/079,954
Reply to Office Action of August 9, 2005

SCHU 204.1 CONT

REMARKS

Claims 51-57 remain pending. Claims 51 and 52 have been amended. With respect to claim 51, the following features of the amendment are noteworthy:

(i) the polypeptide characteristic of passage of HPV infected cells must be one which comprises the amino acid sequence encoded by SEQ ID NO: 1 or 2.

(ii) the first agent of claim 51 is clearly defined.

(iii) the second agent of claim 51 is clearly defined as one which binds the first agent.

With respect to the first objection, original claims are considered part of the specification. Original claim 8 defines the agents. Thus, support is provided for the amendment to claim 51.

Turning to the issues raised by point 3 of the action, the Examiner discusses how the specification allegedly only discloses information relevant to SEQ ID NOS: 1 and 2. Without agreeing with the Examiner's position, the amendment of claims 51 and 52 to recite these sequences renders this rejection moot.

Similarly, the Examiner agrees that claims 51-57 are enabled for what is now claimed, rendering point 4 moot.

With respect to the rejection extending over pages 11-12, applicants submit the attached paper by Wollscheid, et al., Int. J. Cancer, 99:771-775 (2002), supporting their position. This rejection should be withdrawn.

With respect to the prior art rejections, it is noted that the USPTO has already found SEQ ID NOS: 1 and 2 patentable. As such, the amended claims must, per se, be deemed patentable, and a holding to that is urged.

Respectfully submitted,

By 

Norman D. Hanson

Registration No.: 30,946

FULBRIGHT & JAWORSKI L.L.P.

666 Fifth Avenue

New York, New York 10103

(212) 318-3000

(212) 318-3400 (Fax)

Attorney for Applicant

Attachment: Petition for Extension
Wollscheid, et al. Publication